Fluvoxamine for symptomatic outpatients with COVID-19

CMAJ. 2022 Feb 22;194(7):E258. doi: 10.1503/cmaj.220011. Epub 2022 Jan 19.
No abstract available

Publication types

  • Review

MeSH terms

  • Adult
  • COVID-19 Drug Treatment*
  • Fluvoxamine / administration & dosage*
  • Fluvoxamine / adverse effects
  • Humans
  • SARS-CoV-2
  • Selective Serotonin Reuptake Inhibitors / administration & dosage*
  • Selective Serotonin Reuptake Inhibitors / adverse effects

Substances

  • Serotonin Uptake Inhibitors
  • Fluvoxamine